Efficacy and Safety of Two Doses of Formoterol Fumarate MDI (PT005) in Patients With Stable Chronic Obstructive Pulmonary Disease (COPD), Compared to Foradil® Aerolizer® as an Active Control

Pearl Therapeutics

Status and phase: Withdrawn; Phase 2

Conditions: COPD

Treatments: Drug: Inhaled PT005; Drug: Inhaled Placebo; Drug: Formoterol Fumarate 12 µg (Foradil Aerolizer)

Study type: Interventional

Funder types: Industry

Identifiers

NCT01043601

PT0051002

Details and patient eligibility

About

The purpose of this study is to evaluate the safety and efficacy of inhaled formoterol fumarate (7.2 and 9.6 µg ex-actuator) compared to placebo and Foradil Aerolizer in patients with moderate to very severe chronic obstructive pulmonary disease (COPD).

Sex: All

Ages: 40 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Key Inclusion Criteria:

• Signed written informed consent
• 40 - 80 years of age
• Fluency in written and spoken English
• Females of non-child bearing potential or females of child bearing potential with negative pregnancy test; and acceptable contraceptive methods
• Current/former smokers with at least a 10 pack-year history of cigarette smoking
• A measured post- bronchodilator FEV1/FVC ratio of < or = 0.70
• A measured post- bronchodilator FEV1 > or = 750ml or 30% predicted and < or = 80% of predicted normal values
• Competent at using the inhalation device

Key Exclusion Criteria:

• Women who are pregnant or lactating
• Primary diagnosis of asthma
• Alpha-1 antitrypsin deficiency as the cause of COPD
• Active pulmonary diseases
• Prior lung volume reduction surgery
• Abnormal chest X-ray (or CT scan) not due to the presence of COPD
• Hospitalized due to poorly controlled COPD within 12 weeks of Screening
• Poorly controlled COPD, defined as the occurrence of acute worsening of COPD requiring corticosteroids or antibiotics or acute worsening of COPD requiring treatment prescribed by a physician within 6 weeks of screening or between screening and visit 2
• Lower respiratory tract infection requiring antibiotics within 6 weeks of screening
• Clinically significant medical conditions that preclude participation in the study (e.g. clinically significant abnormal ECG or uncontrolled hypertension)
• Positive Hepatitis B surface antigen or Hepatitis C antibody
• Cancer that has not been in complete remission for at least 5 years
• History of hypersensitivity to any beta2-agonists or any study drug component
• History of severe milk protein allergy
• Known or suspected history of alcohol or drug abuse
• Medically unable to withhold short acting bronchodilators for 8-hours
• Use of prohibited medications prior to screening and during the study as specified in the protocol
• Receiving long-term-oxygen or nocturnal oxygen therapy for >12 hours a day
• Participation in acute phase of pulmonary rehabilitation within 4 weeks of screening or will enter acute phase of pulmonary rehabilitation program during study
• Unable to comply with study procedures
• Prior participation in a Pearl PT005 study
• Requires use of a spacer due to poor hand-to-breath coordination

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Triple Blind

---

0 participants in 4 patient groups, including a placebo group

Inhaled PT005 7.2 µg

Experimental group

Treatment:

Drug: Inhaled PT005

Inhaled PT005 9.6 µg

Experimental group

Treatment:

Drug: Inhaled PT005

Inhaled Placebo

Placebo Comparator group

Treatment:

Drug: Inhaled Placebo

Formoterol Fumarate 12 µg (Foradil Aerolizer)

Active Comparator group

Treatment:

Drug: Formoterol Fumarate 12 µg (Foradil Aerolizer)